AbbVie (ABBV) Competitors

Eli Lilly and Company (NYSE:LLY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Is LLY or ABBV more profitable?

Eli Lilly and Company has a net margin of 20.48% compared to AbbVie's net margin of 9.22%. AbbVie's return on equity of 244.01% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	20.48%	71.08%	13.35%
AbbVie	9.22%	244.01%	13.44%

Is LLY or ABBV a better dividend stock?

Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.7%. Eli Lilly and Company pays out 64.9% of its earnings in the form of a dividend. AbbVie pays out 227.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media favor LLY or ABBV?

In the previous week, Eli Lilly and Company had 32 more articles in the media than AbbVie. MarketBeat recorded 57 mentions for Eli Lilly and Company and 25 mentions for AbbVie. Eli Lilly and Company's average media sentiment score of 0.62 beat AbbVie's score of 0.54 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	24 Very Positive mention(s)	11 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor LLY or ABBV?

AbbVie received 126 more outperform votes than Eli Lilly and Company when rated by MarketBeat users. Likewise, 73.34% of users gave AbbVie an outperform vote while only 70.65% of users gave Eli Lilly and Company an outperform vote.

Company	Underperform	Outperform
Eli Lilly and Company	Outperform Votes 1211 70.65%	Underperform Votes 503 29.35%
AbbVie	Outperform Votes 1337 73.34%	Underperform Votes 486 26.66%

Do analysts rate LLY or ABBV?

Eli Lilly and Company presently has a consensus price target of $1,002.22, suggesting a potential upside of 30.54%. AbbVie has a consensus price target of $205.70, suggesting a potential upside of 17.15%. Given Eli Lilly and Company's higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.81
AbbVie	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Which has more risk & volatility, LLY or ABBV?

Eli Lilly and Company has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Which has preferable valuation & earnings, LLY or ABBV?

Eli Lilly and Company has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$40.86B	17.84	$5.24B	$9.25	83.00
AbbVie	$55.53B	5.59	$4.86B	$2.88	60.97

Do institutionals and insiders believe in LLY or ABBV?

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 0.3% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AbbVie beats Eli Lilly and Company on 11 of the 21 factors compared between the two stocks.